GenEndeavor LLC
GenEndeavor LLC is a biotech company dedicated to developing a new generation of diagnostic technologies to enable early detection of genetic and infectious diseases. Their mission is to save lives and improve therapeutic outcomes by creating sensitive, rapid, and affordable point-of-care testing platforms. The company focuses on breaking existing diagnostic barriers, lowering detection limits of rare mutations and pathogens, and advancing accessible diagnostic solutions for diseases such as ovarian cancer, tuberculosis, sepsis, and COVID-19. They are actively involved in research, project development, and collaborations to transform healthcare diagnostics.
Industries
Nr. of Employees
small (1-50)
Products
Rapid multiplex bloodstream pathogen identification test (in development)
A multiplex nucleic acid test intended to detect and identify a large panel of bloodstream infection pathogens and common resistance mutations directly from unprocessed whole blood with rapid turnaround times (goal: under 60 minutes).
Handheld real-time aerosol pathogen monitoring system (in development)
A handheld air sensing system under NIH-funded development to detect and quantify aerosolized pathogens (example use case: SARS-CoV-2) in real-time at the point of presentation.
Point-of-care TB diagnostic for non-sputum pediatric samples (in development)
A rapid, low-cost point-of-care test under development intended to detect Mycobacterium tuberculosis directly from saliva or urine in children, designed for decentralized settings and short turnaround (<10 minutes targeted).
Ultra-sensitive early ovarian cancer mutation screening assay (in development)
An assay platform under development aimed at detecting rare mutations associated with early-stage ovarian cancer to enable very early screening at point-of-care.
Rapid multiplex bloodstream pathogen identification test (in development)
A multiplex nucleic acid test intended to detect and identify a large panel of bloodstream infection pathogens and common resistance mutations directly from unprocessed whole blood with rapid turnaround times (goal: under 60 minutes).
Handheld real-time aerosol pathogen monitoring system (in development)
A handheld air sensing system under NIH-funded development to detect and quantify aerosolized pathogens (example use case: SARS-CoV-2) in real-time at the point of presentation.
Point-of-care TB diagnostic for non-sputum pediatric samples (in development)
A rapid, low-cost point-of-care test under development intended to detect Mycobacterium tuberculosis directly from saliva or urine in children, designed for decentralized settings and short turnaround (<10 minutes targeted).
Ultra-sensitive early ovarian cancer mutation screening assay (in development)
An assay platform under development aimed at detecting rare mutations associated with early-stage ovarian cancer to enable very early screening at point-of-care.
Expertise Areas
- Molecular diagnostics development
- Point-of-care diagnostic design for low-resource settings
- Multiplex nucleic acid assay development
- Infectious disease diagnostics (sepsis, TB, SARS-CoV-2)
Key Technologies
- Non-enzymatic isothermal nucleic acid amplification
- Isothermal nucleic acid amplification
- Multiplex nucleic acid panels
- Direct-from-sample nucleic acid detection (whole blood, saliva, urine)
News & Updates
GenEndeavor was awarded the 2021 NIH Director’s Transformative Research Award to develop a handheld air monitoring system for SARS-CoV-2 detection in real-time at the point of presentation.
GenEndeavor is working on developing a sensitive and specific test for early detection of ovarian cancer, aiming to increase the 5-year survival rate to over 90%.
The FDA granted Breakthrough Device Designation to GenEndeavor’s rapid test for bloodstream infections, which can detect and identify pathogens directly from blood samples in under 60 minutes.
GenEndeavor will present at the BIO-Europe Spring Conference in Barcelona, showcasing their NEAT platform for molecular diagnostics.
Alina Nalyvayko, with expertise in Molecular Biology and m.TB research, joins the team to explore diagnostic solutions for TB.
GenEndeavor will showcase their NEAT platform at the BIO CEO & Investor Conference in New York City.
GenEndeavor was awarded the 2021 NIH Director’s Transformative Research Award to develop a handheld air monitoring system for SARS-CoV-2 detection in real-time at the point of presentation.
GenEndeavor is working on developing a sensitive and specific test for early detection of ovarian cancer, aiming to increase the 5-year survival rate to over 90%.
The FDA granted Breakthrough Device Designation to GenEndeavor’s rapid test for bloodstream infections, which can detect and identify pathogens directly from blood samples in under 60 minutes.
GenEndeavor will present at the BIO-Europe Spring Conference in Barcelona, showcasing their NEAT platform for molecular diagnostics.
Alina Nalyvayko, with expertise in Molecular Biology and m.TB research, joins the team to explore diagnostic solutions for TB.
GenEndeavor will showcase their NEAT platform at the BIO CEO & Investor Conference in New York City.